Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-00217830. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-00217830 SCHEMBL29749575 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2A | |
| Pf-00217830 SCHEMBL29875552 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2A | |
| SCHEMBL5368945 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2A | |
| SCHEMBL5363253 | 0.97 | DRD2 (0.94) | DRD2HTR1AHTR2A | |
| SCHEMBL3399721 | 0.96 | DRD2 (0.93) | DRD2HTR1AHTR2A | |
| Pf-00217830 SCHEMBL4793130 | 0.96 | DRD2 (0.92) | DRD2HTR1AHTR2A | |
| SCHEMBL5224229 | 0.95 | DRD2 (0.90) | DRD2HTR1AHTR2A | |
| SCHEMBL5363657 | 0.91 | DRD2 (0.86) | DRD2HTR1AHTR2A | |
| SCHEMBL5383509 | 0.91 | DRD2 (1.00) | DRD2HTR1AHTR2A | |
| SCHEMBL5366833 | 0.90 | DRD2 (0.82) | DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269242-A1 | Crystalline Salts of 7-[4-(4-Naphthalen-1-Yl-Piperazin-1-Yl)-Butoxy]-3,4-Dihydro-1H-[1,8]Naphthyridine-2-One | BEYLIN VLADIMIR GENUKH | 2008-10-30 | — | — | US | claimed |
| EP-1945638-A2 | CRYSTALLINE SALTS OF 7-[4-(4-NAPHTHALEN-1-YL-PIPERAZIN-1-YL)-BUT OXY]-3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDIN-2-ONE | Pfizer Products Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| JP-4034811-B2 | — | — | 2008-01-16 | — | — | JP | claimed |
| WO-2007052104-A2 | CRYSTALLINE SALTS OF 7-[4-(4-NAPHTHALEN-1-YL-PIPERAZIN-1-YL)-BUT OXY]-3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDIN-2-ONE | PFIZER PRODUCTS INC. (US) | 2007-05-10 | — | — | WO | claimed |
| JP-2007503386-A | — | — | 2007-02-22 | — | — | JP | claimed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | claimed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | claimed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | claimed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | claimed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | DRD2 2/4885HTR1A 191/4885HTR2A 328/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | DRD2 2/4885HTR1A 191/4885HTR2A 328/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | DRD2 2/4885HTR1A 191/4885HTR2A 328/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20080269242-A1 | Crystalline Salts of 7-[4-(4-Naphthalen-1-Yl-Piperazin-1-Yl)-Butoxy]-3,4-Dihydro-1H-[1,8]Naphthyridine-2-One | PKD1, UACA, NAP1L1 | DRD2 3004/4885HTR1A 407/4885HTR2A 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.